Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers. - Oh, Yumi; Jung, Hae Rim; Min, Seoyeon; Kang, Jinjoo; Jang, Dongjun; Shin, Seungjae; Kim, Jiwon; Lee, Sang Eun; Sung, Chang Ohk; Lee, Won-Suk; Lee, Charles; Jeong, Eui Man; et al. (Cancer Letters, 2021)